M
Manuel Cuenca-Estrella
Researcher at Carlos III Health Institute
Publications - 333
Citations - 26900
Manuel Cuenca-Estrella is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Aspergillus fumigatus & Voriconazole. The author has an hindex of 82, co-authored 332 publications receiving 23463 citations.
Papers
More filters
Journal ArticleDOI
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly,Sharon C.-A. Chen,Carol A. Kauffman,William J. Steinbach,John W. Baddley,Paul E. Verweij,Cornelius J. Clancy,John R. Wingard,Shawn R. Lockhart,Andreas H. Groll,Tania C. Sorrell,Matteo Bassetti,Hamdi Akan,Barbara D. Alexander,David R. Andes,Elie Azoulay,Ralf Bialek,Robert W. Bradsher,Stéphane Bretagne,Thierry Calandra,Angela M. Caliendo,Elio Castagnola,Mario Cruciani,Manuel Cuenca-Estrella,Catherine F. Decker,Sujal R. Desai,Brian T. Fisher,Thomas S. Harrison,Claus Peter Heussel,Henrik Jeldtoft Jensen,Christopher C. Kibbler,Dimitrios P. Kontoyiannis,Bart Jan Kullberg,Katrien Lagrou,Frédéric Lamoth,Thomas Lehrnbecher,J. Loeffler,Olivier Lortholary,Johan Maertens,O. Marchetti,Kieren A. Marr,Henry Masur,Jacques F. Meis,C. Orla Morrisey,Marcio Nucci,Luis Ostrosky-Zeichner,Livio Pagano,Thomas F. Patterson,John R. Perfect,Zdenek Racil,Emmanuel Roilides,Marcus Ruhnke,Cornelia Schaefer Prokop,Shmuel Shoham,Monica A. Slavin,David A. Stevens,George Richard Thompson,Jose A. Vazquez,Claudio Viscoli,Thomas J. Walsh,Adilia Warris,L. Joseph Wheat,P. Lewis White,Theoklis E. Zaoutis,Peter G. Pappas +64 more
TL;DR: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Journal ArticleDOI
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Oliver A. Cornely,Matteo Bassetti,Thierry Calandra,Jorge Garbino,Bart Jan Kullberg,O. Lortholary,O. Lortholary,Wouter Meersseman,Murat Akova,Maiken Cavling Arendrup,S. Arikan-Akdagli,Jacques Bille,Elio Castagnola,Manuel Cuenca-Estrella,J.P. Donnelly,Andreas H. Groll,Raoul Herbrecht,William W. Hope,Henrik Jeldtoft Jensen,Cornelia Lass-Flörl,George Petrikkos,Malcolm Richardson,Emmanuel Roilides,Paul E. Verweij,Claudio Viscoli,Andrew J. Ullmann +25 more
TL;DR: This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
Journal ArticleDOI
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Andrew J. Ullmann,José María Aguado,S. Arikan-Akdagli,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Patricia Muñoz,Paul E. Verweij,Adilia Warris,Florence Ader,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary Ann Barnes,Catherine Beigelman-Aubry,Catherine Beigelman-Aubry,Stijn Blot,Stijn Blot,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt,Jacques Cadranel,Jacques Cadranel,Elio Castagnola,Arunaloke Chakrabarti,Manuel Cuenca-Estrella,George Dimopoulos,George Dimopoulos,Jesús Fortún,Jean-Pierre Gangneux,Jorge Garbino,Werner J. Heinz,Raoul Herbrecht,Claus Peter Heussel,Christopher C. Kibbler,Nikolay Klimko,Bart Jan Kullberg,Christoph Lange,Thomas Lehrnbecher,Jürgen Löffler,Olivier Lortholary,J Maertens,O. Marchetti,Jacques F. Meis,Livio Pagano,Patricia Ribaud,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Maurizio Sanguinetti,Donald C. Sheppard,János Sinkó,Anna Skiada,Maria J G T Vehreschild,Claudio Viscoli,Oliver A. Cornely +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Oliver A. Cornely,S. Arikan-Akdagli,Eric Dannaoui,Andreas H. Groll,Katrien Lagrou,Arunaloke Chakrabarti,Fanny Lanternier,Fanny Lanternier,Livio Pagano,Anna Skiada,Murat Akova,Maiken Cavling Arendrup,Teun Boekhout,Teun Boekhout,Anuradha Chowdhary,Manuel Cuenca-Estrella,Tomáš Freiberger,Jesús Guinea,Josep Guarro,S. de Hoog,William W. Hope,Elizabeth M. Johnson,Shallu Kathuria,Michaela Lackner,Cornelia Lass-Flörl,O. Lortholary,Jacques F. Meis,Joseph Meletiadis,Patricia Muñoz,Malcolm Richardson,Emmanuel Roilides,Anna Maria Tortorano,Andrew J. Ullmann,A.D. van Diepeningen,Paul E. Verweij,George Petrikkos +35 more
TL;DR: These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis and strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
Journal ArticleDOI
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.
J. L. Rodriguez-Tudela,Maiken Cavling Arendrup,Francesco Barchiesi,Jacques Bille,Erja Chryssanthou,Manuel Cuenca-Estrella,Eric Dannaoui,David W. Denning,J.P. Donnelly,Françoise Dromer,W. Fegeler,Cornelia Lass-Flörl,Caroline B. Moore,Malcolm Richardson,Per Sandven,Aristea Velegraki,Paul E. Verweij +16 more
TL;DR: A Reference Laboratory for Mycology and Parasitology, National Center for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain.